Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKesson
UBS
Chubb
Moodys
Argus Health

Generated: March 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LEVALBUTEROL HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Levalbuterol Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00064389 Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma Completed Sunovion Phase 3 The purpose of this study is to evaluate the safety of levalbuterol as compared to racemic albuterol based on the frequencies of adverse events reporting during a 12-month period of chronic dosing of adolescent and adult subjects with asthma.
NCT00073814 Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma Completed Sunovion Phase 3 Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects with Asthma
NCT00073827 Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma Completed Sunovion Phase 3 The primary purpose of this study was to investigate the efficacy of levalbuterol compared to a placebo and compared to albuterol in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
NCT00073840 Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma Completed Sunovion Phase 3 The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
NCT00124176 Continuous Levalbuterol for Treatment of Status Asthmaticus in Children Completed Sunovion Phase 4 This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis - Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses - Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. - Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Levalbuterol Hydrochloride

Condition Name

Condition Name for Levalbuterol Hydrochloride
Intervention Trials
Asthma 22
COPD 4
Chronic Obstructive Pulmonary Disease 2
Bronchoconstriction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Levalbuterol Hydrochloride
Intervention Trials
Asthma 20
Pulmonary Disease, Chronic Obstructive 5
Lung Diseases, Obstructive 3
Lung Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Levalbuterol Hydrochloride

Trials by Country

Trials by Country for Levalbuterol Hydrochloride
Location Trials
United States 250
Canada 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Levalbuterol Hydrochloride
Location Trials
California 17
Texas 14
Colorado 12
Virginia 12
Pennsylvania 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Levalbuterol Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Levalbuterol Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 12
Phase 2 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Levalbuterol Hydrochloride
Clinical Trial Phase Trials
Completed 28
Terminated 2
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Levalbuterol Hydrochloride

Sponsor Name

Sponsor Name for Levalbuterol Hydrochloride
Sponsor Trials
Sunovion 25
Johns Hopkins University 1
Fahim Khorfan, MD 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Levalbuterol Hydrochloride
Sponsor Trials
Industry 26
Other 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
UBS
US Department of Justice
Johnson and Johnson
Colorcon
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.